Lv671
2630 积分 2021-09-07 加入
A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin cleavable ADC linkers
4天前
已完结
Antibody–drug conjugates: prospects for the next generation
4天前
已完结
Antibody drug conjugates in the clinic
4天前
已完结
Drugging p53: Barriers, Criteria, and Prospects
10天前
已完结
Translating p53-based therapies for cancer into the clinic
10天前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
17天前
已完结
Corrigendum to “Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer” [Pharmacology & Therapeutics 239 (2022) 108296]
22天前
已完结
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer
22天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
23天前
已完结
HER3-addicted tumors: how biotechs are closing in
23天前
已完结
皖公网安备34019202002308
